Citation Impact
Citing Papers
On‐treatment prediction of sustained response to peginterferon alfa‐2a for HB eAg‐negative chronic hepatitis B patients
2014
HBsAg kinetics in chronic hepatitis D during interferon therapy: on‐treatment prediction of response
2016
Randomised study comparing 48 and 96 weeks peginterferon α-2a therapy in genotype D HBeAg-negative chronic hepatitis B
2012
Long-term therapy of chronic delta hepatitis with peginterferon alfa
2014
Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance
2018 Standout
Hepatitis B surface antigen levels: association with 5-year response to peginterferon alfa-2a in hepatitis B e-antigen-negative patients
2012
COVID-19 infection: Emergence, transmission, and characteristics of human coronaviruses
2020 Standout
Hepatitis B surface antigen levels during the natural history of chronic hepatitis B: A perspective on Asia
2010
Hepatocellular carcinoma
2016 Standout
Clinical utility of quantitative HBsAg in natural history and nucleos(t)ide analogue treatment of chronic hepatitis B: new trick of old dog
2012
Global virus outbreaks: Interferons as 1st responders
2019
A robust cell culture system supporting the complete life cycle of hepatitis B virus
2017 StandoutNobel
Repeated Measurements of Hepatitis B Surface Antigen Identify Carriers of Inactive HBV During Long-term Follow-up
2016
New antiviral targets for innovative treatment concepts for hepatitis B virus and hepatitis delta virus
2016
New insight in the pathobiology of hepatitis B virus infection
2012
Multiple Hepatitis B Virus (HBV) Quasispecies and Immune-Escape Mutations Are Present in HBV Surface Antigen and Reverse Transcriptase of Patients With Acute Hepatitis B
2016
Delivery materials for siRNA therapeutics
2013 Standout
Validation of a stopping rule at week 12 using HBsAg and HBV DNA for HBeAg-negative patients treated with peginterferon alfa-2a
2012
Hepatitis B surface antigen (HBsAg) levels in the natural history of hepatitis B virus (HBV)-infection: A European perspective
2010
The role of quantitative hepatitis B surface antigen revisited
2016
Prediction Models of Long-Term Cirrhosis and Hepatocellular Carcinoma Risk in Chronic Hepatitis B Patients: Risk Scores Integrating Host and Virus Profiles
2013
Cancer immunotherapy utilizing gene-modified T cells: From the bench to the clinic
2015
Response to peginterferon alfa-2a (40KD) in HBeAg-negative CHB: On-treatment kinetics of HBsAg serum levels vary by HBV genotype
2013
A predictive value of quantitative HBsAg for serum HBV DNA level among HBeAg-positive pregnant women
2012
Association Between Level of Hepatitis D Virus RNA at Week 24 of Pegylated Interferon Therapy and Outcome
2015
Hepatocyte-targeted RNAi Therapeutics for the Treatment of Chronic Hepatitis B Virus Infection
2013
Virus associated malignancies: The role of viral hepatitis in hepatocellular carcinoma
2014 StandoutNobel
Inflammation and tumor progression: signaling pathways and targeted intervention
2021 Standout
Non-viral vectors for gene-based therapy
2014 Standout
Review article: current antiviral therapy of chronic hepatitis B
2008
Reduction of covalently closed circular DNA with long-term nucleos(t)ide analogue treatment in chronic hepatitis B
2016
Management of chronic hepatitis B in childhood: ESPGHAN clinical practice guidelines
2013
Hepatitis B surface antigen quantification: Why and how to use it in 2011 – A core group report
2011
HBV-Induced Immune Imbalance in the Development of HCC
2019
Lymphocytes transiently expressing virus-specific T cell receptors reduce hepatitis B virus infection
2017
Immune cell responses are not required to induce substantial hepatitis B virus antigen decline during pegylated interferon-alpha administration
2013
Quantification of HBsAg in nucleos(t)ide-naïve patients treated for chronic hepatitis B with entecavir with or without tenofovir in the BE-LOW study
2014
Review article: chronic hepatitis B – anti‐viral or immunomodulatory therapy?
2010
Targeting the Achilles heel of the hepatitis B virus: a review of current treatments against covalently closed circular DNA
2015 StandoutNobel
Alpharetroviral self-inactivating vectors produced by a superinfection-resistant stable packaging cell line allow genetic modification of primary human T lymphocytes
2016 StandoutNobel
Follow-up and indications for liver biopsy in HBeAg-negative chronic hepatitis B virus infection with persistently normal ALT: A systematic review
2012
Targeting immune cells for cancer therapy
2019
Hepatitis B core-related antigen (HBcrAg) levels in the natural history of hepatitis B virus infection in a large European cohort predominantly infected with genotypes A and D
2015
Performance Evaluation of New Automated Hepatitis B Viral Markers in the Clinical Laboratory
2012
Effects of amino acid substitutions in hepatitis B virus surface protein on virion secretion, antigenicity, HBsAg and viral DNA
2016 StandoutNobel
The Emerging Role of In Vitro-Transcribed mRNA in Adoptive T Cell Immunotherapy
2019 StandoutNobel
Humanized mice efficiently engrafted with fetal hepatoblasts and syngeneic immune cells develop human monocytes and NK cells
2016 StandoutNobel
Nucleoside/nucleotide analogues in the treatment of chronic hepatitis B
2011
EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection
2017 Standout
Risk stratification for hepatitis B virus related hepatocellular carcinoma
2012
Antiviral Treatment of Chronic Hepatitis B Virus (HBV) Infections
2010
Changes of HBsAg and HBV DNA levels in C hinese chronic hepatitis B patients after 5 years of entecavir treatment
2013
Baseline HBsAg and HBcrAg titres allow peginterferon‐based ‘precision medicine’ in HBeAg‐negative chronic hepatitis B patients
2016
Modeling host interactions with hepatitis B virus using primary and induced pluripotent stem cell-derived hepatocellular systems
2014 StandoutNobel
Present and future therapies of hepatitis B: From discovery to cure
2015
Next Generation of Fluorine-Containing Pharmaceuticals, Compounds Currently in Phase II–III Clinical Trials of Major Pharmaceutical Companies: New Structural Trends and Therapeutic Areas
2016 Standout
Serum Levels of Hepatitis B Surface Antigen and DNA Can Predict Inactive Carriers With Low Risk of Disease Progression
2016
Special Issue: KDIGO Clinical Practice Guideline for the Care of Kidney Transplant Recipients
2009 Standout
Sequential Combination Therapy with Pegylated Interferon Leads to Loss of Hepatitis B Surface Antigen and Hepatitis B e Antigen (HBeAg) Seroconversion in HBeAg-Positive Chronic Hepatitis B Patients Receiving Long-Term Entecavir Treatment
2015
New developments in antiviral therapy for chronic hepatitis B
2009
Works of F. Moriconi being referenced
Hepatitis B Surface Antigen Serum Levels Help to Distinguish Active From Inactive Hepatitis B Virus Genotype D Carriers
2010
Immunotherapy of HCC metastases with autologous T cell receptor redirected T cells, targeting HBsAg in a liver transplant patient
2014
Lamivudine-resistant HBV strain rtM204V/I in acute hepatitis B
2013
Hepatitis B virus surface antigen levels: A guide to sustained response to peginterferon alfa-2a in HBeAg-negative chronic hepatitis B # †
2008
Multicenter Evaluation of the Elecsys Hepatitis B Surface Antigen Quantitative Assay
2011